Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Regulatory News In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Federal and state regulatory news updates.

You may also be interested in...



Stryker Receives FDA Warning Letter Following Class I Recall

The FDA letter cites Stryker for failing to notify FDA of a product recall and for illegally marketing devices, including the Neptune waste management system.

News In Brief

House Majority leader floats device tax repeal as fiscal cliff issue. The U.S. Preventative Services Task Force issued draft recommendations with middling support for hepatitis C screening in the general baby-boomer population. More news.

News In Brief

Orthofix settles foreign bribery charges. Cardiosolutions wins $8 million investment for mitral valve technology. OraSure plans $75 million stock offering. More news in brief.

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Medical Device
Latest Headlines

Mosie Baby First To Win FDA Clearance For At-Home DYI Artificial Insemination Kit

“We’re A Pain-Management Company.” Nevro Adds SI Joint Surgery To SCS Business

MDR Changes Aren’t A ‘Catalyst’ For Medtech Investments In Ireland

eSTAR Now Open For PMA Submissions

See All
UsernamePublicRestriction

Register

MT031611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By